Mandate

Vinge advises XVIVO in connection with a directed share issue of MSEK 250

November 01, 2021 Capital Markets and Public M&A

Vinge has advised XVIVO Perfusion AB in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 250 to XVIVO.

The subscription price of SEK 335, which corresponded to the closing price on Nasdaq Stockholm, was determined through an accelerated book-building procedure arranged by Carnegie and Bryan, Garnier & Co. The proceeds will be used for the financing of XVIVO’s acquisition of Star Teams Inc. which was published on the same day as the directed share issue.

Vinge’s team primarily consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026

Vinge has advised Morrow Bank in connection with its issuances of primary capital instruments (AT1) and tier 2 capital bonds (T2)

The issuances comprised perpetual AT1 bonds of NOK 300 million with a floating coupon of 3-month NIBOR + 425 basis points and a first call date in 2031, as well as subordinated Tier 2 bonds of SEK 200 million with a floating coupon of 3-month STIBOR + 325 basis points and a first call date in 2031. The bonds are intended to be admitted to trading on Nasdaq Stockholm.
July 03, 2026

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026